Relmada Therapeutics, Inc. filed a Form 8-K on September 8, 2026, disclosing that Dr. Raj S. Pruthi's employment as Chief Medical Officer - Urology ended on September 3, 2026.

Key Highlights

  • Employment ended: Dr. Raj S. Pruthi's role as Chief Medical Officer - Urology of Relmada Therapeutics, Inc. ended on September 3, 2026.
  • Disclosure item: The departure was reported under Item 8.01 (Other Events) of the current report.
  • Filing date: The report was signed and dated September 8, 2026, by Chief Executive Officer Sergio Traversa.
  • Exchange listing: Relmada Therapeutics common stock, $0.001 par value per share, trades on the NASDAQ Capital Market under the symbol RLMD.

Relmada Therapeutics Discloses End of Chief Medical Officer - Urology Employment

According to the filing, Relmada Therapeutics, Inc. (NASDAQ:RLMD) reported the departure of Dr. Raj S. Pruthi, who had served as the company's Chief Medical Officer - Urology. The filing states that his employment in that capacity ended on September 3, 2026. No additional details regarding the circumstances of the departure, any severance arrangements, or transition plans were included in the disclosure.

The report was filed under Item 8.01, designated as "Other Events," and was signed on behalf of the registrant by Sergio Traversa, Chief Executive Officer, on September 8, 2026. Relmada Therapeutics is incorporated in Nevada and maintains its principal executive offices at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134, according to the filing.

What Was Disclosed

The filing disclosed that Dr. Raj S. Pruthi's employment as Chief Medical Officer - Urology of Relmada Therapeutics, Inc. ended on September 3, 2026. No further details on the departure were provided in the report.